Sarepta (SRPT) PT Raised at Jefferies as BioMarin AdCom Viewed as a Positive But Remains Cautious
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
November 25, 2015 12:09 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $55 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain confident in Eteplirsen approval following Drisapersen's AdCom.
Messer commented, "As expected, most of the discussion yesterday was around inconsistencies in the drisapersen... More
Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer
November 25, 2015 7:19 AM ESTOn Nov. 24, the FDA held an Advisory Committee panel for BioMarin's (NASDAQ: BMRN) Kyndrisa a potential competitor to eteplirsen. The panel highlighted Kyndrisa's significant liabilities and the panel focus included safety concerns then difficult-to-interpret efficacy data.
Why is this a positive for Sarepta... More
